cyc 202 has been researched along with quercetagetin in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (quercetagetin) | Trials (quercetagetin) | Recent Studies (post-2010) (quercetagetin) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 72 | 0 | 46 |
| Protein | Taxonomy | cyc 202 (IC50) | quercetagetin (IC50) |
|---|---|---|---|
| Chain A, Mitogen-activated protein kinase 8 | Homo sapiens (human) | 4.6 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 0.34 | |
| Synapsin-1 | Bos taurus (cattle) | 0.15 | |
| Integrase | Human immunodeficiency virus 1 | 0.6429 | |
| Mitogen-activated protein kinase 8 | Mus musculus (house mouse) | 4.6 | |
| Aurora kinase B | Homo sapiens (human) | 2.62 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brinkjost, T; Ehrt, C; Koch, O | 1 |
1 other study(ies) available for cyc 202 and quercetagetin
| Article | Year |
|---|---|
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
Topics: Binding Sites; Chemistry, Pharmaceutical; Drug Design; Models, Chemical; Proteins | 2016 |